ERBB2 and breast carcinoma: With the gradual relaxation of indications for neoadjuvant patients, the successive publication of clinical research results, and the continuous update of treatment concepts, many viewpoints believe that all HER2-positive locally advanced breast cancer (LABC) patients who meet the criteria for single-target therapy with trastuzumab can consider dual-targeted therapy with trastuzumab combined with pertuzumab during the neoadjuvant therapy stage [6].